Mako Research
Contributor since: 2015
Nothing Has Changed In Over 2 Years, And Akoustis Is Still Virtually Worthless
ShotSpotter: The TAM Is Smaller Than Believed, 60-70% Downside
Sanofi Lobs A Huge Liability Back To Lexicon Pharma With Deal Breakup; Lexicon Is Now Out Of Options And Nearly Out Of Cash
Motorcar Parts Of America: History Of Accounting Fraud, Earnings Look Overstated, Solvency Concerns, Insiders Have Sold
Cryoport Is A Wildly Overvalued No-Moat Business
Cytosorbents: Short Thesis Intact
Cytosorbents: Revenue Could Decline 70%+ In 2022
ViewRay: Failed Product Launch Raises Solvency Questions
T2 Biosystems: Prepare For The Bankruptcy
Collision With Reality Sends Abeona Stock Spiraling Lower
Aerie Pharmaceuticals: Guidance Is Unachievable After Failed Drug Launches; 70%+ Downside
T2 Biosystems: Failed Product Launch And Covenant Violations Suggest 100% Downside
Flexion Is Flexible With The Data, Rigid With The Price
Immunomedics: 35-Year History Of Failure, IMMU-132 Will Not Receive Accelerated Approval, 100% Downside Possible
Akoustis: Strong Sell On Product Obsolescence, Paid Stock Promoters, And Ex-Gottbetter Team Involvement, 96% Downside
ViewRay: Initiate Strong Sell On Questionable Backlog, Product Inferiority, And Bankruptcy Concerns
Innovation Pharmaceuticals (Cellceutix): Still Hopeless, Still Worthless
Cellceutix: Financing Partners Arrested For Alleged Ponzi Scheme, Company Faces Risk Of Death Spiral Liquidity Crunch
Abeona Director Implicated In 'Pump And Dump' Lawsuit With SEC Investigation, Price Target Of Zero
AveXis: More Excuses And More Delay, While Superior Competing Drug Receives Approval For Shipment Next Week
Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside
Workhorse: Strong Sell On Insolvency, Failed USPS Bid, Unviable Products, New Price Target Lowered To $0.00 For 100% Downside
Workhorse Group: Paid Stock Promotion, Financing Partner Expelled From FINRA, Insurmountable Competition, 90%+ Downside
MediciNova: CEO Faces Undisclosed Illegal Kickback Lawsuit, Failed Science, Perplexing Related Party Transactions, -84% Downside
Ocata: Dilution Imminent, SEC Investigation Potentially Underway, Office Appears Empty, Price Target $0.00
Digital Turbine: Rush For The Exits Creates Liquidity Crisis, Enduring Overhang
Digital Turbine: Strong Sell - Ties To Stock Manipulators, Obsolete Technology, Massive Lock-Up Expiration Just Days Away
Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside
LifeLogger: Ties To Stock Promotions, 'Pump-And-Dump' Schemes, Price Target Zero
Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside